{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cellulitis-acute/prescribing-information/doxycycline/","result":{"pageContext":{"chapter":{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline","depth":2,"htmlHeader":"<!-- begin field 5c423a39-ed91-4aef-a4e1-aa3500df9312 --><h2>Doxycycline</h2><!-- end field 5c423a39-ed91-4aef-a4e1-aa3500df9312 -->","summary":"","htmlStringContent":"<!-- begin item 6df3b855-bf0b-487a-a386-aa3500df92b2 --><!-- end item 6df3b855-bf0b-487a-a386-aa3500df92b2 -->","topic":{"id":"c0841d82-0a64-5b27-81dc-9a825d85f1bf","topicId":"6db61277-29ef-49cc-bad1-d0d78d0afc10","topicName":"Cellulitis - acute","slug":"cellulitis-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"84376fdb-da2b-561d-bb40-28b5b1a7e975","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bdf35905-533d-5cb1-bd18-9c1575427a25","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes"},{"id":"f79ca51e-9432-56b1-95de-92ed6133be2b","slug":"update","fullItemName":"Update"}]},{"id":"05002b30-8200-5ccf-b9da-7c96acdb65bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fefb70b6-1d32-5e70-afc6-291fa40b3137","slug":"goals","fullItemName":"Goals"},{"id":"cf84220a-f381-5ca1-aa76-ffb99c4959f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aa32cbb7-29d6-58b6-bcde-7702767672ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7e039433-2afe-5980-93f0-c20c41976610","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d1411fdd-dc83-5f20-9fa4-ad67b69c195a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ce40a600-51e8-5b3a-86c2-d127f03c16eb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff60c523-3d6f-5766-8508-98e8cdcf08f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e8cfe4a-13f2-573c-ab45-7231016746c4","slug":"definition","fullItemName":"Definition"},{"id":"2b7befe3-0fef-5d4e-b00d-bad6742fb93c","slug":"causes","fullItemName":"Causes"},{"id":"96971948-f52b-561c-84f8-8600f3eff2d4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4749dc8a-3f24-5e65-a0a3-5d7665ef3085","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ad3d41f6-595b-505c-b020-918f0e086d3f","slug":"complications","fullItemName":"Complications"},{"id":"82ccb916-06d4-5b29-91e4-90005f3db942","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7305e6df-9b2c-5584-9412-54564432e382","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","fullItemName":"Management","slug":"management","subChapters":[{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"78de19b8-8e80-551f-8112-456ce2e25bb0","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"4600d0c1-4cd1-51ee-87a0-b660f0fa2165","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"29987f8b-20b6-5c1f-8d23-183b415a04fb","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"4b09dc1a-8268-50d6-a164-227a73b3556e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d49b86e1-77b2-58e6-82c0-ea0aa7ee74ed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fe910063-69df-5218-bb78-36f5863db2a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"129f5233-2934-55ad-a561-4eb37861dc10","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"74d5b6b4-ef9d-5fc4-b41b-656b81a7ded8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"44402335-ffeb-5e14-9e77-bb8278ef43d6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"04d7d640-f586-53d9-ac59-804c10dd593d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c50af1ff-f157-5023-92b4-aa07b1c28d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2607239d-fb32-54f5-8882-7320b1e6a583","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field c4a5341b-b99e-429b-8f77-aa3500dfa6de --><h3>What are the contraindications and cautions for doxycyline?</h3><!-- end field c4a5341b-b99e-429b-8f77-aa3500dfa6de -->","summary":"","htmlStringContent":"<!-- begin item f84b6fd0-7b46-400a-9028-aa3500dfa6c6 --><!-- begin field 75675367-0d1b-4cdf-bb48-aa3500dfa6de --><ul><li><strong>Do not prescribe doxycycline </strong>to:<ul><li>Women who are pregnant or breastfeeding, and children younger than 12 years of age — tetracyclines are deposited in growing bone and teeth which can result in discolouration of teeth and occasionally dental hypoplasia.</li></ul></li><li><strong>Prescribe doxycycline with caution </strong>to people with:<ul><li>Hepatic impairment and those receiving potentially hepatotoxic drugs.</li><li>Myasthenia gravis — tetracyclines may increase muscle weakness in people with myasthenia gravis.</li><li>Systemic lupus erythematosus (SLE) — tetracyclines may exacerbate SLE symptoms.</li><li>Renal impairment — avoid excessive doses.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 75675367-0d1b-4cdf-bb48-aa3500dfa6de --><!-- end item f84b6fd0-7b46-400a-9028-aa3500dfa6c6 -->","subChapters":[]},{"id":"a80b5b56-3afe-53b6-b86c-667709c7694a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b7faef52-0296-4fb5-98c5-aa3500dfb2fb --><h3>What are the possible adverse effects of doxycycline?</h3><!-- end field b7faef52-0296-4fb5-98c5-aa3500dfb2fb -->","summary":"","htmlStringContent":"<!-- begin item 5c8f35d5-b40f-436b-865f-aa3500dfb2da --><!-- begin field bacb1dff-4431-423a-a9d5-aa3500dfb2fb --><ul><li><strong>Common adverse effects of doxycycline include</strong> dyspnoea, hypotension, peripheral oedema, and tachycardia.</li><li><strong>Other adverse effects of tetracyclines, including doxycycline, include:</strong><ul><li>Common or very common — angioedema, diarrhoea, headache, Henoch-Schönlein purpura, hypersensitivity, nausea, pericarditis, photosensitivity reaction, skin reactions, exacerbation of systemic lupus erythematosus, and vomiting.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with co-amoxiclav. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li><li>Headache may indicate benign intracranial hypertension. Discontinue treatment if raised intracranial pressure develops.</li></ul></li><li>Uncommon — gastrointestinal discomfort.</li><li>Rare or very rare — arthralgia, decreased appetite, discolouration of thyroid tissue (no abnormalities of thyroid function are known to occur), dysphagia, eosinophilia, flushing, gastrointestinal disorders, haemolytic anaemia, hepatic disorders, idiopathic intracranial hypertension, increased risk of infection, myalgia, neutropenia, oral disorders, pancreatitis, photoonycholysis, pseudomembranous enterocolitis, severe cutaneous adverse reactions (SCARs), Stevens-Johnson syndrome, thrombocytopenia, tinnitus, and vision disorders.<ul><li>Visual disorders may indicate benign intracranial hypertension. Discontinue treatment if raised intracranial pressure develops.</li></ul></li><li>Frequency unknown — dizziness and tooth discolouration.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field bacb1dff-4431-423a-a9d5-aa3500dfb2fb --><!-- end item 5c8f35d5-b40f-436b-865f-aa3500dfb2da -->","subChapters":[]},{"id":"15d92800-11d3-5b7f-a378-437820be94f3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e8009b00-487f-4298-a4e2-aa3500dfc27c --><h3>What are the possible drug interactions of doxycycline?</h3><!-- end field e8009b00-487f-4298-a4e2-aa3500dfc27c -->","summary":"","htmlStringContent":"<!-- begin item 492adb1f-9291-4e13-b25a-aa3500dfc267 --><!-- begin field a81d6d4e-0486-4f1b-9820-aa3500dfc27c --><ul><li><strong>Possible drug interactions of doxycycline include:</strong><ul><li><strong>Antacids</strong> — antacids containing aluminium, bismuth, calcium, or magnesium decreasesthe absorption of doxycycline.<ul><li>Manufacturer advises separate administration (for example by 2–3 hours).</li></ul></li><li><strong>Oral zinc, iron salts, or bismuth preparations</strong> — absorption of doxycycline may be impaired if it is taken with these preparations.<ul><li>Manufacturer advises separate administration (for example by 2–3 hours).</li></ul></li><li><strong>Retinoids</strong> — there is a possible increased risk of benign intracranial pressure if tetracyclines are used concurrently with retinoids (such as isotretinoin).<ul><li>Avoid the concurrent use of tetracyclines and retinoids.</li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are <em>not </em>required during or after courses of tetracyclines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> <hyperlink-marker innertext=\"Contraception - combined hormonal methods\" refid=\"-494585\"></hyperlink-marker>and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions of </strong><strong>doxycycline</strong><strong>, </strong>see the <a data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field a81d6d4e-0486-4f1b-9820-aa3500dfc27c --><!-- end item 492adb1f-9291-4e13-b25a-aa3500dfc267 -->","subChapters":[]},{"id":"57d6657c-dea0-5c26-aa88-2bdfee4262c1","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 8c536f7f-e7c7-4dcb-a186-aa3500dfcff9 --><h3>Can doxycycline be used during pregnancy and breastfeeding?</h3><!-- end field 8c536f7f-e7c7-4dcb-a186-aa3500dfcff9 -->","summary":"","htmlStringContent":"<!-- begin item 7f83b61c-30c4-43a8-9361-aa3500dfcfe5 --><!-- begin field 1f59c73f-3979-471f-8644-aa3500dfcff9 --><ul><li><strong>Pregnancy</strong><ul><li>Doxycycline is contraindicated in women who are pregnant [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>].</li><li>Exposure to doxycycline in early pregnancy has not been firmly associated with any specific malformations, but its use in the second or third trimester can cause discolouration of the teeth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">UKTIS, 2017c</a>]. Effects on skeletal development have been reported in the first trimester in animal studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>].</li></ul></li><li><strong>Breastfeeding</strong><ul><li>The manufacturer states that doxycycline is contraindicated in breastfeeding women as it may cause permanent discolouration of the teeth (yellow-grey-brown) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2017b</a>].</li><li>The NHS Specialist Pharmacy Service (SPS) states that concerns about bone deposition of tetracyclines and possible staining of infant’s dental enamel have not been confirmed, and are unlikely during short-term use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Fenner, 2016b</a>]. In addition, absorption and therefore discoloration of teeth in the infant is also inhibited by calcium in the breastmilk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Fenner, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>].<ul><li>The SPS states that If other antibiotics are not appropriate, tetracycline is the preferred drug from this group. Short-term use (less than 3 weeks duration) is acceptable for most tetracyclines, but long-term use (for example in acne) is not advisable [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Fenner, 2016b</a>].</li></ul></li></ul></li></ul><!-- end field 1f59c73f-3979-471f-8644-aa3500dfcff9 --><!-- end item 7f83b61c-30c4-43a8-9361-aa3500dfcfe5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}